Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (191-200 of 464) with videos related to

Pageof 47
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 19, 2021
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-AnalysisSteven J Bots, Claire E Parker, Johannan F Brandse, et al.
The American Journal of Gastroenterology|August 15, 2012
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registryGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
Journal of Crohn'S & Colitis|May 5, 2018
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's DiseaseBruce E Sands, Chenglong Han, Christopher Gasink, et al.
Journal of Crohn'S & Colitis|September 12, 2018
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI TrialsBrian G Feagan, William J Sandborn, Jean-Frédéric Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 9, 2006
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registryGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
Journal of Hypertension|June 8, 2013
Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2)George K Dresser, Sigrid A E Nelson, Jeffrey L Mahon, et al.
Journal of Crohn'S & Colitis|January 22, 2026
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinibFernando Magro, Gerhard Rogler, Brian G Feagan, et al.
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
The American Journal of Gastroenterology|October 16, 2008
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trialEdward V Loftus, Brian G Feagan, Jean-Frédéric Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 31, 2020
Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based CohortsLester Tsai, Christopher Ma, Parambir S Dulai, et al.
Pageof 47

Showing results (191-200 of 464) with videos related to

Sort By:
Pageof 47
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 19, 2021
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-AnalysisSteven J Bots, Claire E Parker, Johannan F Brandse, et al.
The American Journal of Gastroenterology|August 15, 2012
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registryGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
Journal of Crohn'S & Colitis|May 5, 2018
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's DiseaseBruce E Sands, Chenglong Han, Christopher Gasink, et al.
Journal of Crohn'S & Colitis|September 12, 2018
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI TrialsBrian G Feagan, William J Sandborn, Jean-Frédéric Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 9, 2006
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registryGary R Lichtenstein, Brian G Feagan, Russell D Cohen, et al.
Journal of Hypertension|June 8, 2013
Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2)George K Dresser, Sigrid A E Nelson, Jeffrey L Mahon, et al.
Journal of Crohn'S & Colitis|January 22, 2026
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinibFernando Magro, Gerhard Rogler, Brian G Feagan, et al.
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
The American Journal of Gastroenterology|October 16, 2008
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trialEdward V Loftus, Brian G Feagan, Jean-Frédéric Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 31, 2020
Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based CohortsLester Tsai, Christopher Ma, Parambir S Dulai, et al.
Pageof 47